. 2019 May 17;4:16. doi: 10.1038/s41392-019-0049-6

Table 2.

Candidate biomarkers investigated for association with the pazopanib effect in advanced STS

Candidate biomarker	Reported association
Baseline clinico-pathological characteristics
Histological subtype	•Lower 12wPFR in LPS compared to LMS, SS and heterogeneous ‘other’ subtypes¹⁸
	•No enrichment for particular subtype in long-term responders and/or survivors³⁸
Performance status 0 Low histological grade	•Favorable PFS and OS^6,38
Radiological markers	•Possible superiority of Choi criteria and/or FDG-PET over RECIST 1.1 in categorizing stable disease^47,48
Pharmacodynamic markers
Hypertension	•No association of hypertension with improved PFS or OS in post-hoc analysis of aggregated phase II/III data⁵²
Other on-target toxic effects	•No association of drug-induced proteinuria, hypothyroidism or cardiotoxicity with improved PFS or OS in post-hoc analysis of aggregated phase II/III data⁵⁴
Concomitant gastric acid suppression (GAS)	•Significantly inferior PFS (HR1.49, 95% CI 1.11–1.99, p = 0.008) and OS (HR 1.81, 95% CI 1.31–2.49, p < 0.001) among pazopanib-treated patients who received concomitant GAS⁵⁶
Baseline biological markers
Circulating angiogenic factors	•Association with worse PFS in single study—requires validation⁶¹
Circulating neutrophil-to-lymphocyte ratio	•Raised ratio acts asf a poor prognostic marker but not predictive for pazopanib effect^63,64
Tumor TP53 mutation	•Association between NGS-detected TP53 mutation and improved PFS with pazopanib—single small retrospective study⁶⁵